

**TOXICOLOGICAL PROFILE FOR  
ALDRIN/DIELDRIN**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
Public Health Service  
Agency for Toxic Substances and Disease Registry**

September 2002

## **DISCLAIMER**

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

## UPDATE STATEMENT

A toxicological profile for aldrin/dieldrin was released in 1993. An updated draft for public comment version was released on October 17, 2000. This edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry  
Division of Toxicology/Toxicology Information Branch  
1600 Clifton Road NE, E-29  
Atlanta, Georgia 30333



## FOREWORD

This toxicological profile is prepared in accordance with guidelines\* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.


The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the federal, state, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

  
Julie Louise Gerberding, M.D., M.P.H.  
Administrator  
Agency for Toxic Substances and  
Disease Registry

### \*Legislative Background

The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public law 99–499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed ATSDR to prepared toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. The availability of the revised priority list of 275 hazardous substances was announced in the *Federal Register* on November 17, 1997 (62 FR 61332). For prior versions of the list of substances, see *Federal Register* notices dated April 29, 1996 (61 FR 18744); April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); and February 28, 1994 (59 FR 9486). Section 104(I)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list.

## QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

---

### *Primary Chapters/Sections of Interest*

**Chapter 1: Public Health Statement:** The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance's relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

**Chapter 2: Relevance to Public Health:** The Relevance to Public Health Section evaluates, interprets, and assesses the significance of toxicity data to human health.

**Chapter 3: Health Effects:** Specific health effects of a given hazardous compound are reported by *route of exposure*, by *type of health effect* (death, systemic, immunologic, reproductive), and by *length of exposure* (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

**NOTE:** Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

**Pediatrics:** Four new sections have been added to each Toxicological Profile to address child health issues:

- Section 1.6**     **How Can (Aldrin/Dieldrin) Affect Children?**
- Section 1.7**     **How Can Families Reduce the Risk of Exposure to (Aldrin/Dieldrin)?**
- Section 3.7**     **Children's Susceptibility**
- Section 6.6**     **Exposures of Children**

### **Other Sections of Interest:**

- Section 3.8**     **Biomarkers of Exposure and Effect**
  - Section 3.11**   **Methods for Reducing Toxic Effects**
- 

### **ATSDR Information Center**

**Phone:** 1-888-42-ATSDR or (404) 498-0110     **Fax:** (404) 498-0057  
**E-mail:** [atsdric@cdc.gov](mailto:atsdric@cdc.gov)     **Internet:** <http://www.atsdr.cdc.gov>

The following additional material can be ordered through the ATSDR Information Center:

*Case Studies in Environmental Medicine: Taking an Exposure History*—The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include *Reproductive and Developmental Hazards*; *Skin Lesions and Environmental Exposures*; *Cholinesterase-Inhibiting Pesticide Toxicity*; and numerous chemical-specific case studies.

*Managing Hazardous Materials Incidents* is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

*Fact Sheets (ToxFAQs)* provide answers to frequently asked questions about toxic substances.

---

### ***Other Agencies and Organizations***

*The National Center for Environmental Health (NCEH)* focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. *Contact:* NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

*The National Institute for Occupational Safety and Health (NIOSH)* conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. *Contact:* NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

*The National Institute of Environmental Health Sciences (NIEHS)* is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. *Contact:* NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

---

### ***Referrals***

*The Association of Occupational and Environmental Clinics (AOEC)* has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. *Contact:* AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: [aoec@dgs.dgsys.com](mailto:aoec@dgs.dgsys.com) • AOEC Clinic Director: <http://occ-env-med.mc.duke.edu/oem/aoec.htm>.

*The American College of Occupational and Environmental Medicine (ACOEM)* is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. *Contact:* ACOEM, 55 West Seegers Road, Arlington Heights, IL 60005 • Phone: 847-818-1800 • FAX: 847-818-9266



## CONTRIBUTORS

### CHEMICAL MANAGER(S)/AUTHORS(S):

G. Douglas Hanley, M.D., R.S.  
ATSDR, Division of Toxicology, Atlanta, GA

Dolores A. Beblo, Ph.D.  
David Wohlers, Ph.D.  
Armando Avallone, B.S.  
Stephen Bosch, B.S.  
Daniel Plewak, B.S.  
Syracuse Research Corporation, Syracuse, NY

### THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.



## PEER REVIEW

A peer review panel was assembled for aldrin/dieldrin. The panel consisted of the following members:

1. Dr. William B. Buck, Private Consultant, Consul-Tox, Inc., Tolono, Illinois.
2. Dr. Samuel Epstein, Professor of Environmental and Occupational Medicine, School of Public Health, University of Illinois Medical Center, Chicago, Illinois.
3. Dr. Syed Ghiasuddin, Toxicologist, Office of Water Management, Indiana Department of Environmental Management, Indianapolis, Indiana.
4. Dr. Alan Hall, Private Consultant, Evergreen, Colorado.
5. Dr. James Klaunig, Professor and Director of Toxicology, Indiana University School of Medicine, Indianapolis, Indiana.
6. Dr. Peter Lacouture, Associate Director, Clinical Research, The Purdue Frederick Company, Norwalk, Connecticut.
7. Dr. Fumio Matsumura, Assistant Director, Toxic Substances Program, LEHR Facility, University of California, Davis, California.
8. Dr. Edward Morgan, Assistant Professor, Department of Pharmacology, Emory University, Atlanta, Georgia.
9. Dr. Raghubir Prasad Sharma, Fred C. Davison Distinguished Chair in Toxicology, College of Veterinary Medicine, The University of Georgia, Athens, Georgia.

These experts collectively have knowledge of aldrin/dieldrin's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.



## CONTENTS

FOREWORD .....	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS .....	vii
CONTRIBUTORS .....	ix
PEER REVIEW .....	xi
LIST OF FIGURES .....	xx
LIST OF TABLES .....	xxii
1. PUBLIC HEALTH STATEMENT .....	1
1.1 WHAT ARE ALDRIN AND DIELDRIN? .....	1
1.2 WHAT HAPPENS TO ALDRIN AND DIELDRIN WHEN THEY ENTER THE ENVIRONMENT? .....	3
1.3 HOW MIGHT I BE EXPOSED TO ALDRIN AND DIELDRIN? .....	3
1.4 HOW CAN ALDRIN/DIELDRIN ENTER AND LEAVE MY BODY? .....	4
1.5 HOW CAN ALDRIN/DIELDRIN AFFECT MY HEALTH? .....	5
1.6 HOW CAN ALDRIN/DIELDRIN AFFECT CHILDREN? .....	6
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO ALDRIN OR DIELDRIN? .....	7
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO ALDRIN/DIELDRIN? .....	8
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH? .....	8
1.10 WHERE CAN I GET MORE INFORMATION? .....	10
2. RELEVANCE TO PUBLIC HEALTH .....	13
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO ALDRIN AND DIELDRIN IN THE UNITED STATES .....	13
2.2 SUMMARY OF HEALTH EFFECTS .....	15
2.3 MINIMAL RISK LEVELS (MRLs) .....	19
3. HEALTH EFFECTS .....	25
3.1 INTRODUCTION .....	25
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE .....	25
3.2.1 Inhalation Exposure .....	27
3.2.1.1 Death .....	27
3.2.1.2 Systemic Effects .....	28
3.2.1.3 Immunological and Lymphoreticular Effects .....	32
3.2.1.4 Neurological Effects .....	32
3.2.1.5 Reproductive Effects .....	34
3.2.1.6 Developmental Effects .....	34
3.2.1.7 Cancer .....	34
3.2.2 Oral Exposure .....	37
3.2.2.1 Death .....	37
3.2.2.2 Systemic Effects .....	38

3.2.2.3	Immunological and Lymphoreticular Effects	73
3.2.2.4	Neurological Effects	74
3.2.2.5	Reproductive Effects	77
3.2.2.6	Developmental Effects	79
3.2.2.7	Cancer	81
3.2.3	Dermal Exposure	85
3.2.3.1	Death	86
3.2.3.2	Systemic Effects	87
3.2.3.3	Immunological and Lymphoreticular Effects	93
3.2.3.4	Neurological Effects	94
3.2.3.5	Reproductive Effects	95
3.2.3.6	Developmental Effects	96
3.2.3.7	Cancer	96
3.2.4	Other Routes of Exposure	98
3.3	GENOTOXICITY	99
3.4	TOXICOKINETICS	102
3.4.1	Absorption	102
3.4.1.1	Inhalation Exposure	102
3.4.1.2	Oral Exposure	102
3.4.1.3	Dermal Exposure	106
3.4.2	Distribution	106
3.4.2.1	Inhalation Exposure	106
3.4.2.2	Oral Exposure	107
3.4.2.3	Dermal Exposure	110
3.4.2.4	Other Routes of Exposure	110
3.4.3	Metabolism	111
3.4.3.1	Inhalation Exposure	111
3.4.3.2	Oral Exposure	111
3.4.3.3	Dermal Exposure	114
3.4.4	Elimination and Excretion	114
3.4.4.1	Inhalation Exposure	114
3.4.4.2	Oral Exposure	114
3.4.4.3	Dermal Exposure	116
3.4.4.4	Other Routes of Exposure	116
3.4.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	116
3.5	MECHANISMS OF ACTION	118
3.5.1	Pharmacokinetic Mechanisms	118
3.5.2	Mechanisms of Toxicity	120
3.5.3	Animal-to-Humans	122
3.6	TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS	123
3.7	CHILDREN'S SUSCEPTIBILITY	126
3.8	BIOMARKERS OF EXPOSURE AND EFFECT	130
3.8.1	Biomarkers Used to Identify or Quantify Exposure to Aldrin	132
3.8.2	Biomarkers Used to Characterize Effects Caused by Aldrin	133
3.9	INTERACTIONS WITH OTHER CHEMICALS	134
3.10	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	135
3.11	METHODS FOR REDUCING TOXIC EFFECTS	137
3.11.1	Reducing Peak Absorption Following Exposure	137
3.11.2	Reducing Body Burden	138
3.11.3	Interfering with the Mechanism of Action for Toxic Effects	139
3.12	ADEQUACY OF THE DATABASE	140

3.12.1	Existing Information on Health Effects of Aldrin	141
3.12.2	Identification of Data Needs	141
3.12.3	Ongoing Studies	154
4.	CHEMICAL AND PHYSICAL INFORMATION	157
4.1	CHEMICAL IDENTITY	157
4.2	PHYSICAL AND CHEMICAL PROPERTIES	157
5.	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	161
5.1	PRODUCTION	161
5.2	IMPORT/EXPORT	162
5.3	USE	162
5.4	DISPOSAL	163
6.	POTENTIAL FOR HUMAN EXPOSURE	165
6.1	OVERVIEW	165
6.2	RELEASES TO THE ENVIRONMENT	168
6.2.1	Air	168
6.2.2	Water	169
6.2.3	Soil	169
6.3	ENVIRONMENTAL FATE	169
6.3.1	Transport and Partitioning	169
6.3.2	Transformation and Degradation	175
6.3.2.1	Air	175
6.3.2.2	Water	177
6.3.2.3	Sediment and Soil	179
6.3.2.4	Other Media	180
6.4	LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	180
6.4.1	Air	181
6.4.2	Water	182
6.4.3	Sediment and Soil	185
6.4.4	Other Environmental Media	186
6.5	GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	190
6.6	EXPOSURES OF CHILDREN	195
6.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	199
6.8	ADEQUACY OF THE DATABASE	202
6.8.1	Identification of Data Needs	202
6.8.2	Ongoing Studies	206
7.	ANALYTICAL METHODS	209
7.1	BIOLOGICAL MATERIALS	209
7.2	ENVIRONMENTAL SAMPLES	213
7.3	ADEQUACY OF THE DATABASE	217
7.3.1	Identification of Data Needs	217
7.3.2	Ongoing Studies	218
8.	REGULATIONS AND ADVISORIES	219
9.	REFERENCES	227
10.	GLOSSARY	297

APPENDICES

C. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS ..... A-1

D. USER'S GUIDE ..... B-1

E. ACRONYMS, ABBREVIATIONS, AND SYMBOLS ..... C-1

F. INDEX ..... D-1



**LIST OF FIGURES**

3-1. Levels of Significant Exposure to Aldrin-Oral .....	46
3-2. Levels of Significant Exposure to Dieldrin-Oral .....	60
3-3. Proposed Metabolic Pathway for Aldrin and Dieldrin .....	112
3-4. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance .....	119
3-5. Existing Information on Health Effects of Aldrin/Dieldrin .....	142
6-1. Frequency of NPL Sites with Aldrin Contamination .....	166
6-2. Frequency of NPL Sites with Dieldrin Contamination .....	167
6-3. Aldrin Degradation .....	176



## LIST OF TABLES

3-1. Levels of Significant Exposure to Aldrin-Oral .....	39
3-2. Levels of Significant Exposure to Dieldrin-Oral .....	49
3-3. Levels of Significant Exposure to Aldrin-Dermal .....	88
3-4. Levels of Significant Exposure to Dieldrin-Dermal .....	89
3-5. Genotoxicity of Aldrin/Dieldrin <i>In Vivo</i> .....	103
3-6. Genotoxicity of Aldrin/Dieldrin <i>In Vitro</i> .....	104
3-7. Ongoing Studies on Aldrin and Dieldrin .....	155
4-1. Chemical Identity of Aldrin and Dieldrin .....	158
4-2. Physical and Chemical Properties of Aldrin and Dieldrin .....	159
6-1. Dieldrin Residues in Adult Dietary Components (1980–1982) .....	194
6-2. Calculated Dietary Intakes ( $\mu\text{g}/\text{kg}$ of Body Weight/Day) of Dieldrin for Three Population Groups .....	200
6-3. Ongoing Studies on the Potential for Human Exposure to Aldrin and Dieldrin .....	207
7-1. Analytical Methods for Determining Aldrin/Dieldrin in Biological Materials .....	210
7-2. Analytical Methods for Determining Aldrin/Dieldrin in Environmental Samples .....	214
8-1. Regulations and Guidelines Applicable to Aldrin/Dieldrin .....	220